A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

NCT00467649 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: pramlintide acetate (Symlin)
DRUG: rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])
DRUG: basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])

Sponsor

AstraZeneca